Nxstage Medical, Inc. (NXTM)

[stocktrademan]

$NXTM recent news/filings

bullish 21.88

## source: finance.yahoo.com

Wed, 23 Dec 2015 19:10:52 GMT ~ At the Top of IHI, NxStage Extends Its Rally


read full: http://finance.yahoo.com/news/top-ihi-nxstage-extends-rally-191052536.html
*********************************************************

Tue, 22 Dec 2015 22:32:00 GMT ~ Market Zooms, Alibaba Among 5 Breakouts & Setups


read full: http://finance.yahoo.com/video/market-zooms-alibaba-among-5-223200771.html
*********************************************************

Fri, 11 Dec 2015 19:22:49 GMT ~ A Look at Top Picks of This Billion-Dollar Healthcare-Focused Fund


read full: http://www.insidermonkey.com/blog/a-look-at-top-picks-of-this-billion-dollar-healthcare-focused-fund-401753/
*********************************************************

Fri, 11 Dec 2015 12:50:00 GMT ~ Where Investors Are Going - New Research on NxStage, Clean Energy Fuels, Ultratech and Merit Medical

[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 11, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: NxStage Medical ...

read full: http://finance.yahoo.com/news/where-investors-going-research-nxstage-125000006.html
*********************************************************

Thu, 10 Dec 2015 16:40:28 GMT ~ NxStage Medical, Inc. Earnings Analysis: Q3, 2015 By the Numbers


read full: http://www.capitalcube.com/blog/index.php/nxstage-medical-inc-earnings-analysis-q3-2015-by-the-numbers/
*********************************************************

$NXTM charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NXTM company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NXTM/company-info
Ticker: $NXTM
OTC Market Place: Not Available
CIK code: 0001333170
Company name: NxStage Medical, Inc.
Incorporated In: DE, USA


$NXTM share structure

## source: otcmarkets.com

Market Value: $1,394,435,658 a/o Dec 24, 2015
Shares Outstanding: 63,731,063 a/o Oct 26, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$NXTM extra dd links

Company name: NxStage Medical, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NXTM+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NXTM+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NXTM+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NXTM/news - http://finance.yahoo.com/q/h?s=NXTM+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NXTM/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NXTM/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NXTM+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NXTM
DTCC (dtcc.com): http://search2.dtcc.com/?q=NxStage+Medical%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=NxStage+Medical%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=NxStage+Medical%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NXTM
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001333170&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NXTM/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NXTM/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NXTM&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NXTM
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NXTM/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NXTM+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NXTM+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NXTM
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NXTM
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NXTM+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NXTM/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NXTM+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NXTM.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NXTM
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NXTM/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NXTM/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NXTM
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NXTM
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NXTM:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NXTM
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NXTM



$NXTM DD Notes ~ http://www.ddnotesmaker.com/NXTM

[mlkrborn]

NxStage Increases Revenue Guidance for Fourth Quarter and Full-Year 2013
Date : 01/13/2014 @ 4:05PM
Source : PR Newswire (US)
Stock : Nxstage Medical, Inc. (MM) (NXTM)
Quote : 11.31 -0.18 (-1.57%) @ 4:44PM
NxStage Increases Revenue Guidance for Fourth Quarter and Full-Year 2013
Print
Nxstage Medical (NASDAQ:NXTM)
Intraday Stock Chart
Today : Monday 13 January 2014


LAWRENCE, Mass., Jan. 13, 2014 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today increased its revenue guidance for the fourth quarter and fiscal year ended December 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

For the fourth quarter of 2013, the Company expects to deliver total revenue of approximately $69 million, above the top end of its previously announced guidance range for revenue to be between $67.0 to $68.5 million. This performance is expected to reflect approximately 12% growth in the Home when compared with the fourth quarter of 2012, as a result of solid domestic and international sales.

For the full-year 2013, the Company expects to deliver total revenue of approximately $263 million, above the top end of its previously announced guidance range for revenue to be between $261.0 to $262.5 million. Annual Home revenue growth for 2013 is expected to be approximately 7.5%, at the top end of the Company's previously announced guidance range of 6.5 to 7.5% growth.

The Company also expects net loss for the fourth quarter and the full-year 2013 to be within its previous announced guidance ranges of $5 to $6 million and $18.5 to $19.5 million, respectively, subject to adjustments, including recent litigation settlement costs and certain international tax matters.

"As a result of continued traction with our strategic growth initiatives, Home revenue increased slightly ahead of our expectations in the quarter and we continue to target 15% annual revenue growth in the Home in 2014," stated Jeffrey H. Burbank, Chief Executive Officer. "We also delivered solid revenue growth across our other businesses consistent with our guidance, and ended the year with over $80 million in cash."

Management will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15th at 4:30 p.m. PST. A webcast of the presentation will be made available at http://ir.nxstage.com at the time of the presentation. The Company plans to announce its final audited financial results for the fourth quarter and fiscal year ended December 31, 2013 on Thursday, February 27, 2014 at 9:00 am ET.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

[mlkrborn]

NxStage Increases Revenue Guidance for Q4, expects to deliver total revenue of ~$69 mln, above the top end of its previously announced guidance range for revenue to be between $67-68.5 mln vs $67.7 mln Capital IQ Consensus Est. Co also expects net loss for Q4 to be within its previous announced guidance ranges of $5-6 mln ( NXTM ) : ...

[philife]

NxStage and DARPA's DLT contract. Below is a release that has been circulating on Aethlon Medical's board.

Battelle Memorial Institute, Columbus, Ohio was awarded a $7,057,206 cost-plus-fixed-fee contract modification (HR0011-13-C-0023). This work is for the Dialysis-Like Therapeutics program (DLT). DLT seeks to develop a portable device that can effectively treat sepsis across the military health system; capable of removing dirty blood from the body, separate harmful agents, and return clean blood to the body in a manner similar to dialysis treatment of kidney failure. Work will be performed in Columbus, Ohio (51 percent); San Diego, Calif., (7 percent) and ***Lawrence, Mass.*** The estimated completion date is Feb. 12, 2018. The Defense Advanced Research Projects Agency, Arlington, Va., is the contracting activity

Notice that they talk about how work is being done in Columbus, OH (Battelle who is the Prime), San Diego, CA (Aethlon who has announced a subcontract), and Lawrence, MA (Headquarters of NxStage). It has been well know that the group that won this contract was composed of three entities one is Battelle another is Aethlon and the third is more than likely NxStage. This program is developing the future of extracorporeal treatment technology.

[surf1944]

7:30AM Nxstage Medical reports EPS in-line, revs in-line; guides Q2 EPS below consensus, revs in-line (NXTM) 10.68 : Reports Q1 (Mar) loss of $0.08 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.08); revenues rose 8.2% year/year to $61.6 mln vs the $61.1 mln consensus. Co issues guidance for Q2, sees EPS of ($0.07)-($0.08) vs. ($0.06) Capital IQ Consensus Estimate; sees Q2 revs of $64-65.5 mln vs. $64.75 mln Capital IQ Consensus Estimate.

[surf1944]

7:14AM Nxstage Medical beats by $0.01, beats on revs; guides Q1 EPS, revs below consensus; guides FY13 EPS below consensus, revs in-line (NXTM) 10.85 : Reports Q4 (Dec) loss of $0.04 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.05); revenues rose 14.0% year/year to $65 mln vs the $63.54 mln consensus.

Co issues downside guidance for Q1, sees EPS of ($0.09)-(0.08) vs. ($0.05) Capital IQ Consensus Estimate; sees Q1 revs of $60.5-62.0 mln vs. $63.85 mln Capital IQ Consensus Estimate.

Co issues guidance for FY13, sees EPS of ($0.28)-(0.22) vs. ($0.11) Capital IQ Consensus Estimate; sees FY13 revs of $265-270 mln vs. $268.95 mln Capital IQ Consensus Estimate.

"Taken together with increasing confidence in our ability to drive continued growth with new direct to patient marketing programs, we believe the overall effect of our product execution is that we are better positioned to accelerate adoption of our therapies with much greater potential than in the past. With the benefit of these programs largely expected in 2014, we expect top line 2013 revenue to remain strong and grow at a rate similar with 2012, followed by accelerated success and over 15% annual revenue growth in 2014 and beyond, excluding any benefit of service revenue from NxStage owned centers of excellence.

[surf1944]

8:07AM Nxstage Medical announces CE Mark approval, first clinical use of its single needle for dialysis patients (NXTM) 11.27 : Co announced its single needle technology, OneSite, has received CE Mark approval. In addition, initial patient experiences using this new product have demonstrated its benefits for dialysis patients.

As the requirement for certain medical devices to be sold in the European Union, this CE Mark approval will enable NxStage to make OneSite available in countries where it currently distributes its products, including the United Kingdom, the Nordic countries, Benelux, France, and Italy. Separately, NxStage has also received approval to market this product in Canada.

[surf1944]

8:01AM Nxstage Medical Announces CE Mark Approval for Nocturnal Home Hemodialysis (NXTM) : Co announced CE Mark approval for nocturnal home hemodialysis with the NxStage System One. NxStage expects to begin marketing the System One for nocturnal dialysis in countries that recognize the CE Mark approval process in the second half of 2013

[Penny Roger$]

~ Tuesday! $NXTM ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $NXTM ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=NXTM&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=NXTM&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=NXTM
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=NXTM#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=NXTM+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=NXTM
Finviz: http://finviz.com/quote.ashx?t=NXTM
~ BusyStock: http://busystock.com/i.php?s=NXTM&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=NXTM >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[surf1944]

7:27AM Nxstage Medical beats by $0.01, beats on revs; guides Q1 EPS below consensus, revs in-line; guides FY12 EPS, revs below consensus (NXTM) 20.36 : Reports Q4 (Dec) loss of $0.08 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.09); revenues rose 14.5% year/year to $57 mln vs the $56.25 mln consensus. Co issues guidance for Q1, sees EPS of ($0.09)-(0.11) vs. ($0.06) Capital IQ Consensus Estimate; sees Q1 revs of $56-57 mln vs. $56.94 mln Capital IQ Consensus Estimate. Co issues downside guidance for FY12, sees EPS of ($0.25)-(0.32) vs. ($0.13) Capital IQ Consensus Estimate; sees FY12 revs of $240-245 mln vs. $245.39 mln Capital IQ Consensus Estimate.

[Penny Roger$]

~ Wednesday! $NXTM ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $NXTM ~ Earnings expected on Wednesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=NXTM&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=NXTM&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=NXTM
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=NXTM#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=NXTM+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=NXTM
Finviz: http://finviz.com/quote.ashx?t=NXTM
~ BusyStock: http://busystock.com/i.php?s=NXTM&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=NXTM >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[surf1944]

7:19AM Nxstage Medical reports EPS in-line, beats on revs; guides Q3 EPS in-line, revs above consensus; guides FY11 EPS in-line, revs in-line (NXTM) 16.96 : Reports Q2 (Jun) loss of $0.10 per share, in-line with the Capital IQ Consensus Estimate consensus of ($0.10); revenues rose 22.3% year/year to $53.8 mln vs the $51.1 mln consensus. Co issues mixed guidance for Q3, sees EPS of ($0.09-0.11) vs. ($0.09) Capital IQ Consensus Estimate; sees Q3 revs of $53.5-54.5 mln vs. $52.58 mln Capital IQ Consensus Estimate. Co issues in-line guidance for FY11, sees EPS of ($0.36-0.43) vs. ($0.37) Capital IQ Consensus Estimate; sees FY11 revs of $210-215 mln vs. $211.16 mln Capital IQ Consensus Estimate.

[Insane_Vester]

opps

[surf1944]

NxStage® and Spindial S.p.A. Sign Distribution Agreement for the System One in Italy

http://finance.yahoo.com/news/NxStage-and-Spindial-SpA-Sign-prnews-3215836701.html?x=0&.v=1

[surf1944]

NxStage Reports Second Quarter 2008 Financial Results
Tuesday August 5, 7:05 am ET

LAWRENCE, Mass., Aug. 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM - News), a leading manufacturer of innovative dialysis products, today announced its financial results for the second quarter ended June 30, 2008. Revenues for the second quarter were $31.6 million, compared to $31.0 million in the first quarter of 2008 and $10.0 million in the second quarter of 2007.

Revenues in the Company's home dialysis market were $11.9 million in the second quarter of 2008, compared to $10.5 million in the first quarter of 2008. Revenues in the in-center market, from the Company's Medisystems in-center business, were $15.4 million in the second quarter of 2008, compared to $16.1 million in the first quarter of 2008. Revenues in the critical care market were $4.4 million for the second quarter of 2008, compared to $4.3 million in the first quarter of 2008.

NxStage reported a net loss of $12.5 million, or ($0.32) per share, based on shares outstanding as of June 30, 2008, for the second quarter of 2008, compared with a net loss of $13.9 million, or $(0.38) per share, for the first quarter of 2008, and a net loss of $12.9 million, or ($0.43) per share, for the second quarter of 2007. The 2008 second quarter net loss includes a $2.1 million non-cash gain, recorded in other income, reflecting the liability accounting treatment under SFAS No. 150 for the common stock and warrants issued in connection with the Company's previously announced $43 million private placement.

For the second quarter of 2008, the Company had an Adjusted EBITDA loss, adjusted for stock-based compensation, deferred revenue recognized and the accounting impact of its private equity financing recorded as other income (expense), of $7.7 million, compared to a loss of $8.3 million in the first quarter of 2008, and a loss of $11.6 million in the second quarter of 2007 (see the exhibits for a reconciliation of this non-GAAP measure).

Cash, cash equivalents and short term investments as of June 30, 2008 were $26.4 million. While the Company's balance sheet at June 30, 2008 reflects gross proceeds of $25 million from the first tranche of its $43 million private placement, it does not include the impact of the additional $18 million from the second tranche, which closed on August 1, 2008.

As of the end of the second quarter of 2008, NxStage had increased the number of centers with greater than 10 patients to a total of 67, representing a 22% increase when compared with the first quarter of 2008 and 91% increase when compared with the second quarter of 2007.

"We executed on the strategic initiatives outlined last quarter, further solidifying a business model focused on three target markets, and delivering both improved underlying operations and financial results," stated Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "We remain confident in our ability to grow revenue and achieve profitability in the longer term, creating greater value for our shareholders."

Recent Highlights

-- On August 1, 2008, the Company completed a $43 million private
placement of its common stock and warrants.
-- In July 2008, the Company announced access to demographic and outcomes
information for its growing U.S. daily home hemodialysis patient
population, including the following data points:

-- Survival and transplant rates are notably higher among the NxStage
patient population undergoing home daily therapy vs. reported
figures for conventional, less frequent dialysis treatment. NxStage
patients on home daily hemodialysis experienced a better than 50%
reduction in expected mortality compared to the overall U.S.
hemodialysis patient population. This observed difference was
statistically significant (P<0.0001).
-- Patients of varied size, age, vascular access type, and geographic
location are participating in home daily hemodialysis, indicating
its broad applicability.
-- 92% of the U.S. dialysis population resides within 60 miles of a
center offering NxStage home hemodialysis training, and nearly 80%
are within 30 miles. This indicates that geographic barriers to
initiating daily home hemodialysis are being addressed.

-- In July 2008, NxStage elected Jonathan Silverstein, a General Partner
of OrbiMed Advisors, LLC, to its Board of Directors in connection with
the recently announced private placement.
-- In June 2008, Jeff Smith joined the Company as Vice President and
General Manager, Home Market.


Guidance:

For the third quarter of 2008, the Company expects revenue to be in the range of $30 to $32 million. The Company also expects a net loss in the range of $13.5 to $14.5 million or ($0.30) to ($0.32) per share, excluding any accounting impact of its private equity financing, and an Adjusted EBITDA loss in the range of $7.0 to $8.0 million for the third quarter of 2008.

This release contains non-GAAP financial measures, a reconciliation of the Company's non-GAAP financial measures to their most comparable GAAP financial measure is in the exhibits to this press release.

[surf1944]

NxStage Expands System One(TM) Network Coverage for ESRD Patients
Friday June 27, 10:24 am ET
Names Jeff Smith Vice President And General Manager, Home Market

LAWRENCE, Mass., June 27 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM - News), a leading manufacturer of innovative dialysis products, today announced that based on recent data compiled from its patient database matched with CMS public data, approximately 92 percent of End-Stage Renal Disease (ESRD) patients within the continental United States are now located within a 60 mile radius of a dialysis center which offers System One(TM) therapy.

"We are extremely pleased to have increased ESRD patient and physician access to System One via our comprehensive and growing network of dialysis centers," said Jeff Burbank, Chief Executive Officer. "We are committed to further develop and invigorate these programs to deepen our penetration and extend the quality of life benefits of home dialysis to more patients."

The Company also announced the appointment of Jeff Smith to the newly created position of Vice President and General Manager, Home Market. Mr. Smith joins NxStage from Insulet Corporation, where as Vice President of Marketing and Business Development he played a key role in commercializing a next generation wearable insulin pump for diabetes patients.

"Jeff is a strong addition to our team and rounds out NxStage's leadership capabilities across our three growing markets: home, critical care and in-center," said Burbank.

"Jeff will spearhead efforts intended to create momentum and grow our home market," said Joseph Turk, Senior Vice President, Commercial Operations. "He will be exclusively focused on building awareness and delivering tools that demonstrate the superior clinical and economic benefits associated with our home daily dialysis products to patients, physicians, providers and payors. Jeff brings exceptional marketing and commercial knowledge to this role, and has considerable experience in developing markets for medical devices," said Turk.

Mr. Smith joins two other seasoned executives, John Westman and Mark Florence, who serve as Vice Presidents and General Managers of NxStage's Critical Care and In-Center/Medisystems Markets, respectively. Mr. Florence joined NxStage in January 2008, and Mr. Westman has been leading the critical care team since September 2005.

Mr. Smith served four years with Insulet Corporation after serving for 22 years with Abbott Labs in various roles, most recently as Divisional Vice President of Medisense, Abbott's consumer diabetes care franchise. Prior, Mr. Smith was General Manager of Abbott Diagnostics (Canada) and was Director of Ross Products Sales and Marketing.

[surf1944]

NxStage Announces $43 Million Private Placement of Equity Securities
Friday May 23, 9:50 am ET

LAWRENCE, Mass., May 23 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM - News), a leading manufacturer of innovative dialysis products, today announced a $43 million private placement of its common stock and warrants. The private placement consists of 9.6 million shares of NxStage common stock at a price of $4.50 per share and warrants to purchase 1.9 million shares of common stock at an exercise price of $5.50 per share, which price may be adjusted to $3.00 or $6.50 depending upon whether the Company achieves certain targets relating to the number of End Stage Renal Disease patients prescribed to receive therapy with the NxStage System One as of December 31, 2008. The private placement will be closed in two tranches. The Company has agreed to sell the first tranche of $25 million to funds managed or advised by OrbiMed Advisors LLC ("OrbiMed") on or before May 28, 2008. The Company has agreed to sell the second $18 million tranche to existing NxStage institutional investors. This second tranche is subject to stockholder approval, and is expected to close during the third quarter, after NxStage holds a special meeting of its stockholders to approve this portion of the financing. In connection with the closing of the private placement, NxStage has agreed to appoint one individual nominated by OrbiMed Advisors to fill the vacancy that currently exists on the Company's Board of Directors.

Canaccord Adams Inc. served as NxStage's lead agent and financial advisor in connection with the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities. The shares have not been registered under the Securities Act of 1933 or applicable state securities laws and may not be offered or sold in the United States or any state thereof absent registration under the Securities Act and applicable state securities laws or an applicable exemption from registration requirements. As part of this transaction, NxStage has agreed to file a registration statement covering the resale of the shares of common stock and the shares of common stock issuable upon exercise of the warrants acquired in the private placement.

Important Additional Information

NxStage intends to file with the SEC a proxy statement in connection with the private placement. Investors and security holders of NxStage are urged to read the proxy statement when it becomes available because it will contain important information about NxStage and the private placement. Investors and security holders of NxStage may obtain free copies of the proxy statement when it becomes available at the SEC's website at www.sec.gov, at NxStage's website at www.nxstage.com or by writing to NxStage Medical, Inc., 439 S. Union St., 5th Floor, Lawrence, Massachusetts 01843, Attention: Investor Relations. NxStage, its directors and the affiliates of its directors may be deemed to be participants in the solicitation of proxies with respect to the private placement. A description of the interests in NxStage of its directors and such affiliates is set forth in NxStage's proxy statement for its 2008 annual meeting of stockholders, filed with the SEC on April 29, 2008, and will be set forth in the proxy statement in connection with the private placement when it becomes available.

About OrbiMed Advisors LLC

OrbiMed is the world's largest healthcare-dedicated fund manager. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages a family of venture capital funds and public equity investment vehicles.